Inhibition Of The Synthesis Of Beta-app Or Of The Activity Of The A-beta Peptide In The Choroid Plexus

Abstract

The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of .beta.APP or of the activity of the A.beta. peptide in the choroid plexus.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 14/901655, filed Dec. 28, 2015, which is the National Stage of International Application No. PCT/M2014/062871, filed Jul. 4, 2014, the disclosures of which are incorporated by reference herein.

STATEMENT REGARDING SEQUENCE LISTING

[0002] The sequence listing associated with this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into the specification. The name of the text file containing the sequence listing is 65136_ST25.txt. The text file is 6 KB; was created on Dec. 1, 2017; and is being submitted via EFS-Web with the filing of the specification.

SUMMARY

[0003] The invention relates to means for restoring the physiological function of the precursor of the amyloid protein (.beta.APP) and for reducing the production of .beta.-amyloid peptide, which may be used within the scope of prevention or treatment of neurodegenerative diseases, notably Alzheimer's disease.

DETAILED DESCRIPTION

[0004] The .beta.-amyloid peptide (A.beta. peptide) is the major constituent of extracellular amyloid deposits observed in the brain cortex of patients affected with Alzheimer's disease. This peptide stems from the cleavage of the transmembrane protein .beta.APP (for .beta.-amyloid precursor protein ). It is important to recall that the only source of peptide A.beta. is the .beta.-APP protein and that a reduction of the .beta.APP protein causes ipso facto a reduction in the production of the A.beta. peptide. It must also be recalled that the .beta.APP protein has physiological functions and that one of them is to regulate adult neurogenesis (CAILLE et al., Development, 131, 2173-81, 2004).

[0005] The A.beta. peptide results from the maturation of the PAPP protein via the so called amyloidogenic route, involving the successive action of two protease activities, .beta.-secretase and .gamma.-secretase, which respectively release the N- and C-terminal ends of the peptide.

[0006] The accumulation of A.beta. peptides in the extracellular medium induces alterations of the cell membranes causing massive entry of calcium into the cell and being accompanied by an inflammatory reaction. These lesions would cause neuronal death.

[0007] An alternative proteolytic maturation route of the .beta.APP protein is the so called non-amyloidogenic route; in this route, another enzyme, .alpha.-secretase, cuts the .beta.APP at the middle of the A.beta. sequence. This cleavage prevents the formation of the A.beta. peptide and releases a soluble and secreted form called sAPP, which has neuroprotective properties and a mitogenic function on adult neural cell strains (CAILLE et al., Development, 131, 2173-81, 2004). The production of the sAPP is therefore incompatible with that of the .beta.A4 generated by the action of the beta-secretase (N-terminal) and the gamma-secretase (C-terminal).

[0008] The protein .beta.APP is expressed in many tissues of the organism, and notably by the neurones, including at the brain level.

[0009] The choroid plexus are structures localized at the ventricles, more particularly at the roof of the fourth ventricle and of the junction between the lateral ventricles of the brain and the third ventricle. They consist of an epithelium consisting of ependymal cells associated by narrowed junctions and resting on a basal membrane which separates them from a connective and vascular tissue stroma consisting of a network of fenestrated blood capillaries, and of collagen fibers produced by the fibroblasts present in the stroma.

[0010] The choroid plexuses produce the cerebrospinal liquid (CSL), by playing a role of a selective barrier allowing the passage of certain molecules between the blood and the CSL, and by blocking others. They also synthesize a certain number of proteins, which are secreted in the CSL. Although the presence of .beta.APP in choroid plexuses has been reported (SASAKI et al., Brain Res, 755, 193-201, 1997), its expression level had never been determined before.

[0011] The inventors have now ascertained, during an analysis by sequencing of the RNAs of the epithelial cells of the choroid plexus, that the gene coding for .beta.APP was part of those which were the most strongly expressed in this structure, and that the expression level of this protein in the choroid plexus was much greater than the one observed in other regions of the brain known previously for expressing it at a high level. They also observed a very high expression of the protein APLP-2, which belongs to the same family as .beta.APP and which like the latter may generate by proteolytic maturation a soluble form (sAPLP-2) having neuroprotective and neurotrophic properties, but which, unlike .beta.APP does not form an A.beta. peptide since APLP-2 does not contain the A.beta. sequence (WASCO et al., Proc Natl Acad Sci USA, 89, 10758-62, 1992).

[0012] This observation made by the inventors of the quantitative importance of choroid plexuses as a source of .beta.APP gives the possibility of proposing that this brain structure be targeted for regulating therein the production of .beta.APP, either by increasing it, or by decreasing it. It is clear that decreasing the expression of .beta.APP in choroid plexuses should decrease that of the peptide A.beta.. This structure may also be targeted for strategies aiming at blocking or reducing the activity of the A.beta. peptide.

[0013] The present invention relates to the targeting of the choroid plexus in strategies for regulating the synthesis of the .beta.APP protein or of addressing an inhibitor of the activity of the A.beta. peptide, within the scope of the treatment of a neurodegenerative disease.

[0014] The object of the present invention is accordingly an inhibitor of the synthesis of the .beta.APP protein or of the activity of the A.beta. peptide or an expression vector coding for said inhibitor, for its use in the treatment of a neurodegenerative disease, by targeting said inhibitor in choroid plexuses in order to decrease therein the production or the activity of said A.beta. peptide.

[0015] If one chooses to inhibit the synthesis of the .beta.APP protein, the inhibitor used may be advantageously selected from antisense oligonucleotides and interfering RNAs directed against the gene coding for this protein.

[0016] The functionalities of the .beta.APP protein related to the production of sAPP may be compensated by the protein APLP-2, which is also strongly expressed in choroid plexuses.

[0017] If this compensation is not sufficient, it is possible to overexpress sAPP in a recombinant form in epithelial cells of choroid plexuses. In this case, the antisense oligonucleotide or the iRNA used for inhibiting the synthesis of the .beta.APP protein will be preferentially directed against a region of the gene coding for the C-terminal portion of this protein, in order not to interfere with the synthesis of recombinant sAPP.

[0018] If one chooses to inhibit the activity of the A.beta. peptide, it is possible to use for this purpose an antibody or an antibody fragment selectively directed against this peptide and capable of blocking its activity. Many antibodies having this property are known per se; as non-limiting examples, mention will be made of scFVA.beta..sup.1B, scFVA.beta..sub.KDE.sup.1B (SUDOL et al., Mol Ther, 17, 2031-40, 2009) scFV59 (FUKUCHI et al., Neurobiol Dis, 23, 502-11, 2006), or CBA.beta.42 (ZHANG et al., Neurobiol Dis, 14, 365-79, 2003).

[0019] Vectors which may be used within the scope of present invention for expressing antisense oligonucleotides, iRNAs, sAPP, or antibodies directed against the peptide A.beta., in the cells of the choroid plexus are viral vectors preferentially targeting these cells. For example these are vectors derived from adeno-associated viruses (AAV) of serotypes 2, 4 or 5 (CACHON-GONZALEZ et al., Mol Ther, 20, 1489-500, 2012; DODGE et al., Mol Ther, 18, 2075-84, 2010; DONSANTE et al., Mol Ther, 19, 2114-23, 2011; WATSON et al., Hum Gene Ther, 16, 49-56, 2005).

[0020] Regardless of the selected vector, it is also possible to place the antisense oligonucleotide; the iRNA, the sAPP or the antibody directed against the peptide A.beta., will be placed in the selected vector, under control of a specific promoter of the cells of the choroid plexus; as non-limiting examples of promoters which may be used within this scope, mention will be made of the promoter of the gene CRFR2.beta. (REGEV et al., Proc Natl Acad Sci USA, 107, 4424-9, 2010), the promoter of transthyretin (COSTA et al., Molecular and Cellular Biology, 6, 4697-708, 1986), or that of the gene GPR125 (PICKERING et al., BMC Neuroscience, 9, 97, 2008).

[0021] The choroid plexus also has the advantage of being easily accessible by not very invasive routes, in particular via the injection of pharmacological substances into the venous system and, more favorably, in the retro-orbital sinus which is quite near the basolateral face of the choroid plexus. It is therefore possible to address to the choroid plexus, molecules or viral vectors which may transiently or permanently modify the expression and/or the secretion of .beta.APP, of .beta.A4 and of sAPP by the choroid plexus.

[0022] The object of the present invention is also a method for treating a neurodegenerative disease, comprising the targeting in the choroid plexuses of a patient, of an effective amount of an inhibitor of the synthesis of the .beta.APP protein or of the activity of the A.beta. peptide or of an expression vector coding for said inhibitor, in order to decrease the production or the activity of said A.beta. peptide in the choroid plexuses of said patient.

[0023] Said method may also comprise the targeting in the choroid plexuses of said patient, of an effective amount of a functional soluble form of the .beta.APP protein, for restoring or increasing therein a physiological function of said .beta.APP protein, notably neurogenesis. The functional soluble form of the .beta.APP protein is a soluble protein derived from the .beta.APP protein which retains the physiological functions of the .beta.APP protein; this is notably sAPP. According to the method of the invention, said inhibitor and said soluble form of the .beta.APP protein are administered simultaneously, separately or sequentially.

[0024] The object of the present invention is also a combined preparation, comprising:

[0025] (i) an inhibitor of the synthesis of the .beta.APP protein or of the activity of the A.beta. peptide or an expression vector coding for said inhibitor and

[0026] (ii) a functional soluble form of the .beta.APP protein or an expression vector coding for said soluble form,

[0027] for simultaneous, separate or sequential use in the treatment of a neurodegenerative disease, by targeting the choroid plexuses of the patient in order to decrease therein the production or the activity of said A.beta. peptide and restore or increase a physiological function of said .beta.APP protein, notably neurogenesis.

[0028] Neurodegenerative diseases which may be treated according to the invention are notably the sporadic and family forms of Alzheimer's disease.

DESCRIPTION OF THE DRAWINGS

[0029] The present invention will be better understood by means of the additional description which follows, which refers to non-limiting examples demonstrating the expression of .beta.APP in choroid plexuses and describing the construction of viral vectors giving the possibility of regulating this expression or inhibiting the activity of the .beta.A4 peptide, as well as to the appended drawings wherein:

[0030] FIG. 1 illustrates the relative levels of the mRNAs of the genes App, Ap1p1 and Ap1p2 added to those of the housekeeping gene HPRT, in the 4.sup.th ventricle (ChP 4V), the lateral ventricles (ChP LV), the hippocampus (Hc), the subventricular area (SVZ) and the primary visual cortex (V1) of mice about eight weeks old.

[0031] FIG. 2 illustrates the detection of the transmembrane forms and secreted of the protein .beta.APP in the cerebrospinal liquid and the choroid plexus. A. Western Blot with an antibody directed against the N-terminal portion of the PAPP protein (extracellular APP domain), specific to the secreted form. B. Western Blot with an antibody directed against the C-terminal portion of the .beta.APP protein (C terminal APP), specific to the transmembrane form. CSFrat: cerebrospinal liquid of rats. CSFh: human cerebrospinal liquid. Mouse plexus: mouse choroid plexus.

[0032] FIG. 3 illustrates the specific targeting of the choroid plexuses by the AAV of serotype 5 (AAV5). The GFP activity of the brain of mice bearing the gene coding for GFP but only expressing it after recombination, was analyzed after injection into the cerebral ventricles, of an AAV5 either bearing or not the gene coding for the CRE recombinase. A. AAV5-CRE. B. control AAV5.

[0033] FIG. 4 illustrates the recombination of the .beta.APP gene in the choroid plexus. A. Schematic illustration of the non-recombinant .beta.APP gene (APPflox) and recombined by the CRE recombinase (APP.DELTA.) in the APP.sup.flox/flox mouse line. APP.sup.flox/flox mice were injected with the protein CRE-Tat or a vehicle as a control into the cerebral ventricles. 15 days after the injection, the genomic DNA of the choroid plexus (plexus), of the hippocampus, of the brain cortex (cortex) and of the retina were analyzed by PCR (B) and the amount of protein .beta.APP in the choroid plexus was quantified by a Western Blot (C).

[0034] FIG. 5 illustrates the decrease in the number of proliferative cells (Ki67+) in the subventricular zone (SVZ), after decrease in the .beta.APP protein in the choroid plexus by genetic recombination of the .beta.APP gene.

[0035] FIG. 6 illustrates the decrease of .beta.APP mRNA (A) and of .beta.APP protein (B) in Hela cells transfected with an iRNA targeting the peptide A.beta..

EXAMPLES

Example 1

Expression of the .beta.APP Protein in Choroid Plexuses

[0036] We compared the expression level of PAPP and of two close molecules, APLP-1 and APLP-2, in the choroid plexus, the hippocampus, the subventricular zone and the primary visual cortex of a mouse of about eight weeks old.

[0037] After dissecting the tissues, the RNAs were extracted and the abundance of messenger RNAs for the genes APP, APLP1 and APLP2 determined by RT-qPCR by primers specific to each gene. The expression levels are reported relatively to that of a housekeeping gene, HPRT. The results are illustrated by FIG. 1 and Table 1 below.

[0038] Caption of FIG. 1 and of Table 1: 4.sup.th ventricle: ChP 4V; lateral ventricles: ChP LV; hippocampus: Hc); subventricular zone: SVZ; primary visual cortex: V1.

TABLE-US-00001 TABLE 1 App Apip1 Apip2 ChP 4V 2.07 0.82 2.61 ChP LV 1.80 0.86 3.28 SVZ 0.82 1.03 1.19 Hc 1.00 1.00 1.00 V1 1.58 1.15 1.59

[0039] These results clearly show that the choroid plexus expresses twice to three times more APP and APLP2 transcripts than the other structures.

Example 2

The Entire .beta.APP is Present in the Choroid Plexus and its Soluble Form is Secreted in the CSL

[0040] The choroid plexus of a rodent was analyzed by Western blot with an antibody directed against the C-terminal portion of PAPP (FIG. 2B). The antibody reveals a signal at 105 and 120 kDa corresponding to the entire and transmembrane form of .beta.APP. The presence of secreted .beta.APP (sAPP) in the cerebrospinal liquid (CSL) of the rodent and of humans was sought by Western blot with an antibody directed against the N-terminal portion of the protein (therefore extracellular and potentially secreted after cleavage by the alpha-secretase). The antibody reveals a signal around 90 kDa corresponding to the cleaved and secreted form of PAPP (sAPP) in the CSL (FIG. 2A).

Example 3

The AAV of Serotype 5 (AAV5) Specifically Targets the Choroid Plexuses for Genetic Recombination

[0041] Previously we showed that the fusion protein of the CRE recombinase with the peptide vector derived from the TAT protein of the HIV (CRE-TAT) injected into the cerebral ventricles of adult mice is capable of inducing a specific genomic recombination in the choroid plexus (SPATAZZA et al., Cell Reports 3: 1815-1823, 2013).

[0042] In order to demonstrate a viral vector specifically targets the choroid plexus, an AAV5 either bearing or not the gene coding for the CRE recombinase was injected into the cerebral ventricles of mice bearing the gene coding for GFP but only expressing it after recombination by CRE recombinase. FIG. 3A demonstrates that the virus has access to the choroid plexus but does not infect the neighboring parenchyma and that the CRE expressed by the viral genome induces expression of GFP in a large amount of cells of the choroid plexus.

Example 4

The Gene .beta.APP May be Recombined in the Choroid Plexus

[0043] Adult APP.sup.flox/flox mice (MALLIM et al., Genesis 48: 200-206, 2010; FIG. 4A), were injected with the carrier or the CRE-TAT protein into the cerebral ventricles. Fifteen days later, the genomic DNA was extracted from different regions of the brain and analyzed by PCR. The gel of FIG. 4B demonstrates that the gene of the .beta.APP was specifically recombined in the choroid plexus, excluding other structures of the central nervous system like the retina, the neocortex or the hippocampus. Analysis by Western blot confirms that the amount of .beta.APP protein is significantly decreased in the choroid plexus 15 days after recombination (FIG. 4C).

Example 5

Decrease of .beta.APP in the Choroid Plexus Causes a Reduction in the Number Of Proliferative Cells in the Sub-Ventricular Zone

[0044] The proliferative cells of mice in which the gene .beta.APP has been recombined (Example 4) were identified by means of an antibody directed against the protein Ki67 (proliferation marker) and then counted by stereology. Relatively to the control mice, the mice in which the gene .beta.APP was recombined have their neurogenesis (number of proliferative cells) decreased significantly (FIG. 5).

Example 6

The Exogenus sAPP Injected into the Cerebral Ventricles Increases Neurogenesis in SVZ

[0045] The recombinant sAPP was injected into the cerebral ventricles of adult wild mice of six weeks old. One and three weeks later, the proliferative cells are identified by means of the marker Ki67 as in Example 5. An increase in the number of proliferative cells is expected.

Example 7

Construction of a Viral Vector for Expressing sAPP in the Choroid Plexus

[0046] The sequence coding for sAPP (nt 201-2213 of NM_000484, Genbank, which is set forth herein as SEQ ID NO: 3), is inserted into a lentiviral vector derived from pTRIP.DELTA.U3 [PGK+beta2/IRES2+eGFP+WPRE] (MASKOS et al., 2005, Nature 436: 103-107), downstream from the promoter FoxJ1 which is not active in neuronal cells (ZHANG et al., 2007, Am J Respir Cell Mol Biol 36: 515-519), and upstream from the sequence coding for an intermediate peptide (P2A, KIM et al, 2011, PloS one 6(4) e18556) followed by that of the GFP.

[0047] The resulting plasmid (pLFsAPP-P2Gfp) is co-transfected with plasmids coding for the viral proteins required in a suitable packing line (HEK 293T). The viral particles are then recovered in the culture medium, concentrated and titrated.

[0048] The obtained lentiviruses are injected into the retro-orbital sinus, from where they have preferred access to the choroid plexus.

Example 8

Construction of a Vector for Expressing an Antibody with a Simple Chain Against Ba4

[0049] The mRNAs extracted from hybridomas expressing an anti-.beta.A4 monoclonal antibody such as scFV A.beta..sup.1B, scFVA.beta..sub.KDE.sup.1B (SUDOL et al., 2009, supra), scFV59 (FUKUCHI et al., 2006, supra) or CBA.beta.42 (ZHANG et al., 2003, supra), are used for separately amplifying the variable portions of the heavy and lightweight chains according to the procedure described by BARBAS et al. (2001, "Phage display, a laboratory manual", CSHL Press) adapted in the laboratory (LESAFFRE et al., Neural Development, 2, 2, 2007). Position on either side of the coding sequence of a long flexible linker, these minigenes are fused with a label formed with 6 tag myc, and introduced into the bi-cistronic lentiviral vector described above (Cf Example 7).

[0050] The resulting plasmid (pLFsabA4-P2Gfp) is used for producing lentiviruses which are injected as described above (cf. Example 7).

Example 9

Construction of a Small Interfering RNA for Decreasing the Expression of the .beta.APP Gene and the Amount of .beta.APP Protein

[0051] A small interfering RNA (iRNA or siRNA) was prepared; its sequence 5'-AUGAACUUCAUAUCCUGAGTC-3' (SEQ ID NO: 1) complementary of the sequence 5'-GACTCAGGATATGAAGTTCAT-3' (SEQ ID NO: 2) is specific to the DNA domain coding for a portion of the human A.beta. peptide. Human cells of the HeLa line are cultivated and 24 h later a control siRNA (i.e., corresponding to no human sequence in the database BLAST) or the iRNA was transfected (100 pmol/100,000 cells). 48 hours later, the cells were lysed and the .beta.APP mRNA level analysed by RT-qPCR and the amount of .beta.APP protein by Western blot. After transfection with RNAi, the .beta.APP mRNA level is significantly decreased (relatively to the cells transfected with the control siRNA), (FIG. 6A). The amount of .beta.APP protein is also decreased significantly in the cells transfected with iRNA (FIG. 6B).

Example 10

Use of an AAV5 Expressing a Small Interfering RNA for Decreasing the Expression of .beta.APP in the Choroid Plexus and Delaying the Formation of Senile Plates in the Brain of APP/PS1 Mice

[0052] An AAV5 expressing the shRNA corresponding to the small iRNA of Example 9 under the control of the promoter U6 was constructed. The mice bearing a "Swedish" mutation in the gene coding for PAPP and bearing a mutation in the gene coding for PS1 developed A.beta. aggregates (senile plates) in the hippocampus and the neocortex from the age of 4 months. These mice are injected with AAV5-shRNA in the cerebral ventricles between 3 and 5 months and at 6 months, the size and the amount of the A.beta. deposits are identified by marking with Thioflavin S and anti-A.beta. antibodies are analysed. A decrease in the number of plates is expected.

Sequence CWU 1

1

3121RNAartificial sequencesynthetic oligoribonucleotide 1augaacuuca uauccugagu c 21221DNAartificial sequencesynthetic oligonucleotide 2gactcaggat atgaagttca t 2133648DNAHomo Sapiensmisc_featureEncoding amyloid beta precursor protein (APP) 3ggatcagctg actcgcctgg ctctgagccc cgccgccgcg ctcgggctcc gtcagtttcc 60tcggcagcgg taggcgagag cacgcggagg agcgtgcgcg ggggccccgg gagacggcgg 120cggtggcggc gcgggcagag caaggacgcg gcggatccca ctcgcacagc agcgcactcg 180gtgccccgcg cagggtcgcg atgctgcccg gtttggcact gctcctgctg gccgcctgga 240cggctcgggc gctggaggta cccactgatg gtaatgctgg cctgctggct gaaccccaga 300ttgccatgtt ctgtggcaga ctgaacatgc acatgaatgt ccagaatggg aagtgggatt 360cagatccatc agggaccaaa acctgcattg ataccaagga aggcatcctg cagtattgcc 420aagaagtcta ccctgaactg cagatcacca atgtggtaga agccaaccaa ccagtgacca 480tccagaactg gtgcaagcgg ggccgcaagc agtgcaagac ccatccccac tttgtgattc 540cctaccgctg cttagttggt gagtttgtaa gtgatgccct tctcgttcct gacaagtgca 600aattcttaca ccaggagagg atggatgttt gcgaaactca tcttcactgg cacaccgtcg 660ccaaagagac atgcagtgag aagagtacca acttgcatga ctacggcatg ttgctgccct 720gcggaattga caagttccga ggggtagagt ttgtgtgttg cccactggct gaagaaagtg 780acaatgtgga ttctgctgat gcggaggagg atgactcgga tgtctggtgg ggcggagcag 840acacagacta tgcagatggg agtgaagaca aagtagtaga agtagcagag gaggaagaag 900tggctgaggt ggaagaagaa gaagccgatg atgacgagga cgatgaggat ggtgatgagg 960tagaggaaga ggctgaggaa ccctacgaag aagccacaga gagaaccacc agcattgcca 1020ccaccaccac caccaccaca gagtctgtgg aagaggtggt tcgagaggtg tgctctgaac 1080aagccgagac ggggccgtgc cgagcaatga tctcccgctg gtactttgat gtgactgaag 1140ggaagtgtgc cccattcttt tacggcggat gtggcggcaa ccggaacaac tttgacacag 1200aagagtactg catggccgtg tgtggcagcg ccatgtccca aagtttactc aagactaccc 1260aggaacctct tgcccgagat cctgttaaac ttcctacaac agcagccagt acccctgatg 1320ccgttgacaa gtatctcgag acacctgggg atgagaatga acatgcccat ttccagaaag 1380ccaaagagag gcttgaggcc aagcaccgag agagaatgtc ccaggtcatg agagaatggg 1440aagaggcaga acgtcaagca aagaacttgc ctaaagctga taagaaggca gttatccagc 1500atttccagga gaaagtggaa tctttggaac aggaagcagc caacgagaga cagcagctgg 1560tggagacaca catggccaga gtggaagcca tgctcaatga ccgccgccgc ctggccctgg 1620agaactacat caccgctctg caggctgttc ctcctcggcc tcgtcacgtg ttcaatatgc 1680taaagaagta tgtccgcgca gaacagaagg acagacagca caccctaaag catttcgagc 1740atgtgcgcat ggtggatccc aagaaagccg ctcagatccg gtcccaggtt atgacacacc 1800tccgtgtgat ttatgagcgc atgaatcagt ctctctccct gctctacaac gtgcctgcag 1860tggccgagga gattcaggat gaagttgatg agctgcttca gaaagagcaa aactattcag 1920atgacgtctt ggccaacatg attagtgaac caaggatcag ttacggaaac gatgctctca 1980tgccatcttt gaccgaaacg aaaaccaccg tggagctcct tcccgtgaat ggagagttca 2040gcctggacga tctccagccg tggcattctt ttggggctga ctctgtgcca gccaacacag 2100aaaacgaagt tgagcctgtt gatgcccgcc ctgctgccga ccgaggactg accactcgac 2160caggttctgg gttgacaaat atcaagacgg aggagatctc tgaagtgaag atggatgcag 2220aattccgaca tgactcagga tatgaagttc atcatcaaaa attggtgttc tttgcagaag 2280atgtgggttc aaacaaaggt gcaatcattg gactcatggt gggcggtgtt gtcatagcga 2340cagtgatcgt catcaccttg gtgatgctga agaagaaaca gtacacatcc attcatcatg 2400gtgtggtgga ggttgacgcc gctgtcaccc cagaggagcg ccacctgtcc aagatgcagc 2460agaacggcta cgaaaatcca acctacaagt tctttgagca gatgcagaac tagacccccg 2520ccacagcagc ctctgaagtt ggacagcaaa accattgctt cactacccat cggtgtccat 2580ttatagaata atgtgggaag aaacaaaccc gttttatgat ttactcatta tcgccttttg 2640acagctgtgc tgtaacacaa gtagatgcct gaacttgaat taatccacac atcagtaatg 2700tattctatct ctctttacat tttggtctct atactacatt attaatgggt tttgtgtact 2760gtaaagaatt tagctgtatc aaactagtgc atgaatagat tctctcctga ttatttatca 2820catagcccct tagccagttg tatattattc ttgtggtttg tgacccaatt aagtcctact 2880ttacatatgc tttaagaatc gatgggggat gcttcatgtg aacgtgggag ttcagctgct 2940tctcttgcct aagtattcct ttcctgatca ctatgcattt taaagttaaa catttttaag 3000tatttcagat gctttagaga gatttttttt ccatgactgc attttactgt acagattgct 3060gcttctgcta tatttgtgat ataggaatta agaggataca cacgtttgtt tcttcgtgcc 3120tgttttatgt gcacacatta ggcattgaga cttcaagctt ttcttttttt gtccacgtat 3180ctttgggtct ttgataaaga aaagaatccc tgttcattgt aagcactttt acggggcggg 3240tggggagggg tgctctgctg gtcttcaatt accaagaatt ctccaaaaca attttctgca 3300ggatgattgt acagaatcat tgcttatgac atgatcgctt tctacactgt attacataaa 3360taaattaaat aaaataaccc cgggcaagac ttttctttga aggatgacta cagacattaa 3420ataatcgaag taattttggg tggggagaag aggcagattc aattttcttt aaccagtctg 3480aagtttcatt tatgatacaa aagaagatga aaatggaagt ggcaatataa ggggatgagg 3540aaggcatgcc tggacaaacc cttcttttaa gatgtgtctt caatttgtat aaaatggtgt 3600tttcatgtaa ataaatacat tcttggagga gcaaaaaaaa aaaaaaaa 3648

Claims

1-9. (canceled)

10. A method of decreasing the synthesis of .beta.APP in the choroid plexus of a patient affected with Alzheimer's disease, comprising administering an expression vector coding for an inhibitor of the .beta.APP protein to said patient targeting the choroid plexuses of said patient, said inhibitor being selected from antisense oligonucleotides and interfering RNAs directed against the gene coding of said .beta.APP protein.

11. The method of claim 10, wherein said vector is derived from an adeno-associated virus.

12. The method of claim 10, wherein said antisense oligonucleotide or interfering RNA is directed against a region of the mRNA coding for the C-terminal portion of the endogenous .beta.APP protein in order not to interfere with the synthesis of a soluble functional recombinant form of the .beta.APP protein encoded by nucleic acids 201-2213 of SEQ ID NO:3.

13. The method of claim 10, wherein said method reduces the A.beta. peptide synthesis.

14. The method according to claim 10, wherein the vector is derived from an adeno-associated virus of serotype 2, 4, or 5.

15. The method according to claim 10, wherein said Alzheimer's disease is a sporadic or family form of Alzheimer's disease.

16. The method according to claim 10, wherein said vector is administered by injection into the retro-orbital sinus.

17. The method according to claim 10, wherein said vector is administered by injection into the venous system.

18. The method according to claim 10, wherein said vector is combined with a soluble functional recombinant form of the .beta.APP protein, wherein the antisense oligonucleotide or interfering RNA is directed against a region of the mRNA coding for the C-terminal portion of the endogenous .beta.APP protein in order not to interfere with the synthesis of the soluble functional recombinant form of the .beta.APP protein encoded by nucleic acids 201-2213 of SEQ ID NO:3.

19. The method of claim 18, wherein said soluble recombinant .beta.APP protein is overexpressed through a viral vector.